Kane Biotech (TSXV:KNE) has completed a major transformation during the past year, relaunching its animal health business, expanding into human health, raising non-dilutive financing, and hiring a new executive team, including a chief scientific officer and assembling a scientific advisory board.
“This company has flown under the radar for many years, disappointing investors with missed milestones. But in the past year, our achievements have exceeded our expectations and we’re ready to grow the business in a big way,” CEO, Marc Edwards, says in an interview with BioTuesdays.
Mr. Edwards, who moved into the executive suite at Kane in September 2018, says a key element in the turnaround has been securing some $10-million in non-dilutive funding and building a new executive and scientific team.
In the veterinary channel within its animal health segment, where Kane has licensed its technology to partner, UK-based Dechra Veterinary Products (LON:DPH), Dechra is entering new marketing regions with its Vetradent line of products and expanding its product portfolio. Kane also is expanding its bluestem line of oral care pet products within the pet specialty retail channel into higher volume market segments in the U.S., Europe and China, as well as growing its online sales of the bluestem product line.
|
|
